Less Ads, More Data, More Tools Register for FREE

Reneuron Share News (RENE)

Reneuron Information

Buy RENE Shares
Add RENE to Watchlist
Add RENE to Alert

This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange

Share Price is delayed by 15 minutes

Share Price: 3.275

Bid: 0.00

Ask: 0.00

Change: 0.00 (0.00%)

Spread: 0.00 (0.00%)

Open: 0.00

High: 0.00

Low: 0.00

Prev. Close: 3.275

RENE Live Price

Last checked at -

ReNeuron Group Appoints Ex-Glaxo Executive Owen To Board

Fri, 04th Dec 2015 09:15

LONDON (Alliance News) - Stem cell therapy development company ReNeuron Group PLC on Friday said it has appointed Mike Owen as a non-executive director with immediate effect.

Owen is the former senior vice-president for biopharmaceutical research at GlaxoSmithKline PLC, the FTSE 100-listed drugmaker.

He also will sit on the ReNeuron's Scientific Advisory Board.

ReNeuron shares were down 1.0% to 2.8475 pence on Friday.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News

5 May 2015 06:55

ReNeuron Gets Approval For US Trial For Retinal Cell Therapy Product

17 Apr 2015 11:25

ReNeuron Sees Positive Data From Long Term Follow-Up Of CTX Trial

13 Apr 2015 06:57

ReNeuron Files For US Phase I/II Trial In Retinitis Pigmentosa

1 Apr 2015 09:23

ReNeuron Reduces Board, But Bolsters Management Team

30 Jan 2015 12:45

UK DIRECTOR DEALINGS SUMMARY: ASOS CEO Sells GBP20 Million In Shares

30 Jan 2015 11:32

DIRECTOR DEALINGS: ReNeuron Group Directors Buy Shares

8 Sep 2014 07:34

UK MORNING BRIEFING: Scotland-Exposed Stocks Lead Opening Declines

8 Sep 2014 07:06

ReNeuron Appoints Olav Hellebø As Chief Executive Officer

2 Sep 2014 08:51

Reneuron on track for clinical milestones as studies get underway

Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials. The phase II trial for the ReN001 cell therapy candidate for stroke disability and the phase I trail for ReN009 cell therapy candidate for critical limb ischaemia have bot

2 Sep 2014 08:24

ReNeuron Group Says Core Therapeutic Programme On Track

2 Sep 2014 07:26

UK MORNING BRIEFING: Weir Group Leads Firm London Market On Upgrade

2 Sep 2014 05:24

UK AGM, EGM Calendar - Week Ahead

1 Sep 2014 15:12

UK AGM, EGM Calendar - Week Ahead

1 Sep 2014 05:24

UK AGM, EGM Calendar - Week Ahead

29 Aug 2014 15:04

UK AGM, EGM Calendar - Week Ahead